Acelot

Executive Summary

Acelot is a private biotechnology company headquartered in San Diego, California, founded in 2018. The company leverages artificial intelligence and machine learning to advance small molecule therapeutics targeting TDP-43, a protein critically involved in neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS). TDP-43 dysfunction is a key driver of the inflammatory cascade leading to motor neuron death, making it a compelling target for disease-modifying therapy. Acelot's integrated AI platform aims to accelerate the discovery and optimization of novel compounds that modulate TDP-43 pathology. With a focused approach on a validated yet challenging target, Acelot operates in a high-need area where current treatments offer limited benefit. The company's early-stage pipeline is undisclosed, but its AI-driven strategy positions it to identify lead candidates efficiently. The convergence of AI with small molecule drug discovery offers potential for faster timelines and reduced costs. While still in preclinical stages, Acelot's innovative platform and clear biological rationale provide a foundation for future clinical development. Success in the TDP-43 space could address a significant unmet need in ALS and related neurodegenerative disorders.

Upcoming Catalysts (preview)

• Q4 2026Announcement of Preclinical Lead Optimization Data70% success
• Q2 2027Series A or B Funding Round60% success
• Q1 2027Presentation at Major ALS Conference50% success